Drug Type CAR-T |
Synonyms CHT102 allogeneic CAR T cells(Tianjin Medical University Cancer Institute and Hospital), CHT-102 |
Target |
Action inhibitors |
Mechanism MSLN inhibitors(Mesothelin inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic Cancer | Phase 1 | China | 25 Dec 2024 | |
Mesothelin positive Solid Tumors | Clinical | China | 06 May 2024 | |
Mesothelin positive Solid Tumors | Clinical | China | 06 May 2024 |